U.S. Markets open in 5 mins

The Amedisys (NASDAQ:AMED) Share Price Is Up 549% And Shareholders Are Delighted

Simply Wall St

We think all investors should try to buy and hold high quality multi-year winners. And highest quality companies can see their share prices grow by huge amounts. Don't believe it? Then look at the Amedisys, Inc. (NASDAQ:AMED) share price. It's 549% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. In contrast, the stock has fallen 9.1% in the last 30 days. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report.

We love happy stories like this one. The company should be really proud of that performance!

See our latest analysis for Amedisys

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

Over half a decade, Amedisys managed to grow its earnings per share at 58% a year. This EPS growth is higher than the 45% average annual increase in the share price. So one could conclude that the broader market has become more cautious towards the stock.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

NasdaqGS:AMED Past and Future Earnings, March 11th 2020

It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. Dive deeper into the earnings by checking this interactive graph of Amedisys's earnings, revenue and cash flow.

A Different Perspective

We're pleased to report that Amedisys shareholders have received a total shareholder return of 43% over one year. However, the TSR over five years, coming in at 45% per year, is even more impressive. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.

Amedisys is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.